Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

TENS of thousands of Brits are estimated to be unknowingly living with the silent heart condition that nearly killed ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

Jason "JJ" Facey, of Taunton, died of a previously undiagnosed heart ailment last month during his freshman year at ...

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on ...

For people having surgery unrelated to their hearts, new guidelines detail how to manage heart and stroke risks before, ...

Keith Gandal, professor of English in the Division of Humanities and the Arts at The City College of New York, and his ...

Capricor Therapeutics (CAPR) stock gains as company plans to seek FDA approval for its lead candidate deramiocel (CAP-1002) ...

Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. Edgewise stock soars on positive data from an early-stage study ...

Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...

The 2024 guideline for cardiovascular management of adults undergoing noncardiac surgery reflects a decade of updates and new ...